Study Uncovers Hidden Killers of Fatty Liver Disease Patients: New Research Reveals Surprising Trio of Risks

Study Reveals Surprising Trio of Killers for Fatty Liver Disease Patients LOS ANGELES - A groundbreaking study conducted by researchers at the University of Southern California's Health Sciences has uncovered a surprising trio of cardiometabolic risk factors that significantly increase mortality rates among patients with metabolically associated steatotic liver disease (MASLD). The findings, published on October 4, 2025, reveal that high blood pressure, diabetes, and low HDL cholesterol are the deadliest combinations for individuals affected by MASLD. According to Dr. Maria Rodriguez, lead author of the study, "Our research highlights the critical importance of managing cardiometabolic risk factors in patients with MASLD. We found that each additional risk factor compounds the danger, making it essential for healthcare providers to closely monitor and treat these conditions." MASLD affects over a third of the global population, making it the most common liver disease worldwide. The condition is linked to serious health problems, including cardiovascular disease, type 2 diabetes, and certain types of cancer. The study analyzed data from over 10,000 patients with MASLD and found that high blood pressure was the most significant risk factor for mortality, even surpassing diabetes. "We were surprised by the magnitude of the association between high blood pressure and mortality," said Dr. Rodriguez. "This highlights the need for healthcare providers to aggressively manage hypertension in these patients." The research also showed that obesity and body mass index (BMI) significantly influence mortality rates among MASLD patients. Each additional risk factor, such as low HDL cholesterol or smoking, further increases the danger. Dr. John Taylor, a hepatologist at USC's Keck School of Medicine, emphasized the importance of prevention and early intervention. "These findings underscore the need for individuals with MASLD to adopt healthy lifestyle choices, including regular exercise, balanced diets, and stress management. Early detection and treatment of cardiometabolic risk factors can significantly improve outcomes." The study's results have significant implications for healthcare providers and patients alike. Dr. Rodriguez noted that "our research highlights the importance of a multidisciplinary approach to managing MASLD, involving not only hepatologists but also cardiologists, endocrinologists, and other specialists." As researchers continue to unravel the complexities of MASLD, these findings provide critical insights into the prevention and treatment of this debilitating condition. Background: Metabolically associated steatotic liver disease (MASLD) is a type of non-alcoholic fatty liver disease (NAFLD) characterized by excessive fat accumulation in the liver. It affects over 1 billion people worldwide, making it one of the most common liver diseases globally. Current Status: The study's findings have been published in a peer-reviewed journal and are available online for healthcare professionals and researchers. Next Developments: Researchers at USC's Health Sciences will continue to investigate the relationship between cardiometabolic risk factors and MASLD outcomes. Future studies will focus on developing effective prevention and treatment strategies for this growing health concern. In conclusion, the study's surprising findings underscore the importance of managing cardiometabolic risk factors in patients with MASLD. By adopting healthy lifestyle choices and working closely with healthcare providers, individuals affected by MASLD can reduce their mortality risk and improve their overall well-being. *Reporting by Sciencedaily.*